# Research on Human Insulin rDNA Safety and Efficacy in Patients With Type 2 Diabetes Mellitus

> **NCT05161741** · PHASE4 · COMPLETED · sponsor: **Getz Pharma** · enrollment: 238 (actual)

## Conditions studied

- Adverse Drug Event
- Effect of Drug
- Type 2 Diabetes Treated With Insulin

## Interventions

- **DRUG:** Insulin

## Key facts

- **NCT ID:** NCT05161741
- **Lead sponsor:** Getz Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-01
- **Primary completion:** 2022-11-30
- **Final completion:** 2022-11-30
- **Target enrollment:** 238 (ACTUAL)
- **Last updated:** 2023-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05161741

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05161741, "Research on Human Insulin rDNA Safety and Efficacy in Patients With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05161741. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*